Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes by Follo, M, Pellagatti, A, Armstrong, R, Ratti, S, Mongiorgi, S, De Fanti, S, Bochicchio, M, Russo, D, Gobbi, M, Miglino, M, Parisi, S, Martinelli, G, Cavo, M, Luiselli, D, McCubrey, J, Suh, P, Manzoli, L, Boultwood, J, Finelli, C, Cocco, L